Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal – Endpoints News
Endpoints News |
Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal
Endpoints News Just days ahead of Vas Narasimhan's jump into the CEO's spot, Novartis has swooped in with a $170 million deal to grab ex-US rights on Spark Therapeutics' Luxturna, the first true gene therapy to get a US approval. The pharma giant is paying $105 … Novartis strikes $170m deal for ex-US rights to gene therapy for blindness Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for … Spark licenses blindness gene therapy rights outside US to Novartis |
